Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

培美曲塞 彭布罗利珠单抗 医学 卡铂 内科学 肿瘤科 肺癌 危险系数 安慰剂 化疗 无进展生存期 顺铂 置信区间 癌症 病理 免疫疗法 替代医学
作者
Delvys Rodríguez‐Abreu,Steven Powell,Maximilian J. Hochmair,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,G. Speranza,F. De Angelis,Manuel Dómine,Susanna Y. Cheng,Helge Bischoff,Nir Peled,Martin Reck,Rita L. Hui,Edward B. Garon,Michael Boyer,Takayasu Kurata,Jing Yang,M. Catherine Pietanza,Francis Ribeiro de Souza
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:32 (7): 881-895 被引量:417
标识
DOI:10.1016/j.annonc.2021.04.008
摘要

In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed-platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed-platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab.Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators' choice of cisplatin (75 mg/m2) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Patients assigned to placebo plus pemetrexed-platinum could cross over to pembrolizumab upon progression if eligibility criteria were met. The primary endpoints were OS and PFS.After a median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.46-0.69] and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of programmed death-ligand 1 expression. Objective response rate (ORR) (48.3% versus 19.9%) and time to second/subsequent tumor progression on next-line treatment (PFS2; HR, 0.50; 95% CI, 0.41-0.61) were improved in patients who received pembrolizumab plus pemetrexed-platinum. Eighty-four patients (40.8%) from the placebo plus pemetrexed-platinum group crossed over to pembrolizumab on-study. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus pemetrexed-platinum and 66.8% of patients receiving placebo plus pemetrexed-platinum. Fifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off.Pembrolizumab plus pemetrexed-platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed-platinum, with manageable toxicity. These findings support first-line pembrolizumab plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZsJJkk发布了新的文献求助10
刚刚
励志发SCI完成签到 ,获得积分10
刚刚
杨颜静完成签到,获得积分10
1秒前
ellen完成签到,获得积分10
1秒前
三点水完成签到,获得积分10
1秒前
1秒前
Gauss完成签到,获得积分0
1秒前
虚无完成签到,获得积分10
1秒前
1秒前
suky发布了新的文献求助10
1秒前
1秒前
破碎虚空完成签到,获得积分10
2秒前
learning完成签到,获得积分10
2秒前
朝颜完成签到,获得积分10
2秒前
唠叨的觅海完成签到,获得积分10
2秒前
害羞大雁完成签到,获得积分10
2秒前
星辰大海的应助被付一鸣采纳,获得10
2秒前
2秒前
慕遥完成签到,获得积分10
2秒前
篱篱清发布了新的文献求助10
2秒前
xiaozw发布了新的文献求助10
3秒前
3秒前
3秒前
壬壬爱学习完成签到 ,获得积分10
3秒前
皮皮发布了新的文献求助10
3秒前
万能图书馆的应助被TQZZ采纳,获得10
3秒前
3秒前
3秒前
帅气yumin发布了新的文献求助10
3秒前
阿恒完成签到,获得积分20
3秒前
junjie完成签到,获得积分10
4秒前
4秒前
drake完成签到,获得积分10
4秒前
阿媛呐完成签到,获得积分10
4秒前
呼呼哈哈发布了新的文献求助10
4秒前
百分之九十的烦恼完成签到,获得积分10
5秒前
司菁完成签到,获得积分10
5秒前
Shiyuzz完成签到 ,获得积分10
5秒前
与风同行完成签到 ,获得积分10
5秒前
xrwwww发布了新的文献求助10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162